The HR+/HER2−, HR+/HER2+, and HR−/HER2+ subtypes had a significantly higher risk of having positive lymph nodes, whereas the HR−/HER− subtype was associated with a reduced risk of lymph node metastasis (Fig. 1). This evidence concerns the gene HR and metastatic malignant neoplasm in the lymph nodes.